hipoallergin (paziņots 2008.) tablete
leovit nutrio - tablete
neocate® lcp hipoalerģisks pulveris
sia "nutricia" - pulveris
neocate® lcp hipoalerģisks pulveris
sia "nutricia" - pulveris
neocate® lcp hipoalerģisks pulveris
sia ''nutricia'' 40103070928 gustava zemgala gatve 74, rīga, lv-1039, latvija - pulveris - cits - Īpašiem medicīniskiem nolūkiem paredzēta pārtika
tőpfer lactana® ha1 pulveris
lj pro, sia 40003855031 braslas iela 27-23, rīga, lv-1084 - pulveris - cits - hipoalerģisks mākslīgais maisījums zīdaiņiem no dzimšanas
nan h.a. 1 pulveris
Ārvalstu komersanta „uab nestle baltics” pārstāvniecība 40006007337 duntes iela 11, rīga, lv-1013 - pulveris - cits - hipoalerģisks mākslīgais piena maisījums zīdaiņiem.
entresto
novartis europharm limited - sacubitril, valsartan - sirdskaite - angiotensīna ii antagonisti, citas kombinācijas, līdzekļi, kas iedarbojas uz renin-angiotensīna sistēmu - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
neparvis
novartis europharm limited - sacubitril, valsartan - sirdskaite - agents, kas iedarbojas uz renīna-angiotenzīna sistēmu - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
singulair mini 4 mg granulas
n.v. organon, netherlands - montelukasts - granulas - 4 mg
rybrevant
janssen-cilag international n.v. - amivantamab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.